Abbott

TriClip™
Transcatheter
Edge-to-Edge Repair

bRIGHT STUDY
REAL-WORLD REGISTRY

bRIGHT STUDY 2-YEAR DATA

Objective

Evaluating the safety and effectiveness of TriClip™ TEER in patients with severe or greater tricuspid regurgitation (TR) in a real-world, post-market setting.[1]

Study Design

Prospective, single-arm, multicenter registry (**511** subjects at **26** sites in Europe).[1]

Mean Age[1]
79 ± 7 Years

80%
NYHA[1]
Functional Class III/IV

Studied in an elderly, fragile, real-world patient population.[1]

Exceptional Safety at 30 Days[2]

98%
Freedom from MAEs

99%
Survival

0%
New Pacemaker Implantation

0%
Device Embolization or Thrombosis

REMARKABLE AND SUSTAINED TR REDUCTION AT 1 AND 2 YEARS[1,3]



83%
TR moderate or less at 2 years[3]

Paired analysis shown. If 30-day TR was unavailable, discharge was used.
Imaging data adjudicated by echocardiography core lab.

"We see very **short learning curves** and the ability to adopt the therapy **safely and effectively**. We see a **great safety profile** and confirm the previous effectiveness results of the TRILUMINATE trial. It's confirmed looking at much more centers and **reflecting real-world practice**."*

Prof. Dr. Philipp Lurz
bRIGHT Principal Investigator

For U.S. audience, see Important Safety Information referenced within.
For audiences outside of the U.S., always check the regulatory status of the device in your region.

PROVEN SAFE AND EFFECTIVE IN A DIVERSE SET OF PATIENT ANATOMIES

Broad Population of Patients Anatomies[1,4]

2.5–7.6 cm
RANGE OF ANNULAR DIAMETERS[4]

2.6–20.8 mm
MEASURED GAP SIZES[4]

21%
OF PATIENTS WITH >3 LEAFLETS[4]

23%
OF PATIENTS HAD A PACEMAKER LEAD[1]

Life-changing Outcomes at 1 and 2 Years[1,3]



Improvement in KCCQ-OS Score at 1 Year[1]
(Not measured at 2 years)



NYHA Class I/II at 2 years[3]

For U.S. audience, see Important Safety Information referenced within.
For audiences outside of the U.S., always check the regulatory status of the device in your region.

Significant Reduction in Heart Failure Hospitalization[3]



Mortality at 2 Years Not Significantly Different Among Individuals With Moderate, Mild, or Trace/None TR at 30 Days[3]



AE = adverse events
CV = cardiovascular
KCCQ-OS = Kansas City Cardiomyopathy Questionnaire Overall Summary
MAE = major adverse event
NYHA = New York Heart Association
TEER = transcatheter edge-to-edge repair
TR = tricuspid regurgitation

1. Lurz P, Rommel KP, Schmitz T, et al. Real-world 1-year results of tricuspid edge-to-edge repair from the bRIGHT Study. *J Am Coll Cardiol*. 2024;84(7):607-616. doi:10.1016/j.jacc.2024.05.006
2. Lurz P et al. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Acute Results from the bRIGHT Study. Presented at: EuroPCR; May 17, 2023; Paris, France.
3. Bekeredjian R. Two-year Real-world Outcomes for Tricuspid Edge-to-Edge Repair: the bRIGHT study. Presented at EuroPCR 2025; May 20, 2025; Paris, France.
4. Lurz P, Schueler R, Lapp H, et al. Real-world Evidence Shows Successful Treatment of a Broad Patient Population with TriClip Edge-to-Edge Repair: Initial Observations from the bRIGHT TriClip Study. Presented at EuroPCR; May 17-20, 2022; Paris, France.

For U.S. audience only.

Rx Only

Important Safety Information

TRICLIP™ G4 SYSTEM

INDICATIONS

The TriClip™ G4 System is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are at intermediate or greater risk for surgery and in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team.

CONTRAINDICATIONS

The TriClip™ G4 System is contraindicated in patients with the following conditions: Intolerance, including allergy or untreatable hypersensitivity, to procedural anticoagulation; Untreatable hypersensitivity to Implant components (nickel-titanium alloy, cobalt-chromium alloy); Active endocarditis or other active infection of the tricuspid valve.

POTENTIAL ADVERSE EVENTS

The following events have been identified as possible complications of the TriClip G4 Procedure. Allergic reactions or hypersensitivity to latex, contrast agent, anaesthesia, device materials and drug reactions to anticoagulation, or antiplatelet drugs; Additional treatment/surgery from device-related complications; Bleeding; Blood disorders (including coagulopathy, hemolysis, and heparin induced thrombocytopenia (HIT)); Cardiac arrhythmias (including conduction disorders, atrial arrhythmias, ventricular arrhythmias); Cardiac ischemic conditions (including myocardial infarction, myocardial ischemia, unstable angina, and stable angina); Cardiac perforation; Cardiac tamponade; Chest pain; Death; Dyspnea; Edema; Embolization (device or components of the device); Endocarditis; Fever or hyperthermia; Fluoroscopy and transesophageal echocardiogram (TEE) related complications: Skin injury or tissue changes due to exposure to ionizing radiation, Esophageal irritation, Esophageal perforation, Gastrointestinal bleeding; Hypotension/hypertension; Infection including: Septicemia; Nausea or vomiting; Pain; Pericardial effusion; Stroke/cerebrovascular accident (CVA) and transient ischemic attack (TIA); System organ failure: Cardio-respiratory arrest, Worsening heart failure, Pulmonary congestion, Respiratory dysfunction or failure or atelectasis, Renal insufficiency or failure, Shock (including cardiogenic and anaphylactic); Thrombosis; Tricuspid valve complications, which may complicate or prevent later surgical repair, including: Chordal entanglement/rupture, Single leaflet device attachment (SLDA), Dislodgement of previously implanted devices, Tissue damage, Tricuspid valve stenosis, Worsening, persistent or residual regurgitation; Vascular access complications which may require additional intervention, including: Wound dehiscence, Bleeding of the access site, Arteriovenous fistula pseudoaneurysm, aneurysm, dissection, perforation (rupture), vascular occlusion, Embolism (air, thrombus), Peripheral nerve injury; Venous thrombosis (including deep vein thrombosis) and thromboembolism (including pulmonary embolism).

*The testimonial does not provide any indication, guide, warranty or guarantee as to the response patients may have to the treatment or effectiveness of the product or therapy in discussion. Opinions about the treatment discussed can and do vary and are specific to the individual's experience and might not be representative of others.

CAUTION: Product(s) intended for use by or under the direction of a physician. Prior to use, reference to the Instructions for Use, inside the product carton (when available) or at https://www.eifu.abbott/ for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

For U.S. audience, see Important Safety Information referenced within. For audiences outside of the U.S., always check the regulatory status of the device in your region.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

Abbott
3200 Lakeside Dr., Santa Clara, CA. 95054 USA Tel: 1.800.227.9902

www.structuralheart.abbott

Abbott